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ttp://dx.doi.org/10.1016/j.jmoldx.2013.02.004Reliable breakpoint cluster region (BCR)eAbelson (ABL) 1 measurement is essential for optimal
management of chronic myelogenous leukemia. There is a need to optimize quality control, sensitivity,
and reliability of methods used to measure a major molecular response and/or treatment failure. The
effects of room temperature storage time, different primers, and RNA input in the reverse transcription
(RT) reaction on BCR-ABL1 and b-glucuronidase (GUSB) cDNA yield were assessed in whole blood
samples mixed with K562 cells. BCR-ABL1 was measured relative to GUSB to control for sample loading,
and each gene was measured relative to known numbers of respective internal standard molecules to
control for variation in quality and quantity of reagents, thermal cycler conditions, and presence of PCR
inhibitors. Clinical sample and reference material measurements with this test were concordant
with results reported by other laboratories. BCR-ABL1 per 103 GUSB values were signiﬁcantly reduced
(P Z 0.004) after 48-hour storage. Gene-speciﬁc primers yielded more BCR-ABL1 cDNA than random
hexamers at each RNA input. In addition, increasing RNA inhibited the RT reaction with random
hexamers but not with gene-speciﬁc primers. Consequently, the yield of BCR-ABL1 was higher with
gene-speciﬁc RT primers at all RNA inputs tested, increasing to as much as 158-fold. We conclude that
optimal measurement of BCR-ABL1 per 103 GUSB in whole blood is obtained when gene-speciﬁc primers
are used in RT and samples are analyzed within 24 hours after blood collection. (J Mol Diagn 2013, 15:
391e400; http://dx.doi.org/10.1016/j.jmoldx.2013.02.004)Supported by National Cancer Institute grant R21CA138397.
Disclosure: J.C.W. has equity interest in and serves as a consultant for
Accugenomics, which developed the internal standards used in this study.Chronic myelogenous leukemia (CML) represents 15% of all
adult leukemias in Western populations.1 This malignancy is
caused by a chromosomal translocation, t(9:22)(q34;q11);
a segment of the breakpoint cluster region (BCR) gene from
chromosome 22 (region q11) is fused to a site within the
Abelson (ABL1) gene from chromosome 9 (region q34).2,3
Most BCR breakpoints occur within exons e12 to e16 (b1
to b5; alias major breakpoint cluster region) and fuse to ABL1
exon 2 breakpoints, resulting in e13a2 (b2a2) or e14a2 (b3a2)
fusion transcripts that encode 210-kDa proteins.4 The BCR-
ABL1 fusion protein is a constitutively active tyrosine
kinase responsible for the uncontrolled proliferation observed
in CML.5e7 For the past decade, ﬁrst-line therapy for chronic-
phase CML has been imatinib mesylate (Novartis Pharma-
ceuticals, Basel, Switzerland), which inhibits the tyrosine
kinase activity of the BCR-ABL1 protein.8,9 Imatinib
mesylate binds to the ATP-binding pocket of the BCR-ABL1
fusion protein, stabilizing it in its inactive form.10 Althoughstigative Pathology
.second-generation tyrosine kinase inhibitors, such as dasati-
nib (Bristol-Myers Squibb Company, Princeton, NJ) and
nilotinib (Novartis Pharmaceuticals), have been used in
imatinib-resistant or intolerant patients with CML, recent
studies show promise in these agents as more potent ﬁrst-line
therapies for those newly diagnosed with chronic-phase
CML.11e16
After treatment, a major molecular response (MMR) is
deﬁned, based on results from the International Randomized
Interferon versus STI-571 study,17 as a 3-log10 reduction from
a standardized median baseline value in the level of measured
BCR-ABL1 transcript. In the International Randomized
Interferon versus STI-571 study, patients with a BCR-ABL1
value at or lower than the MMR within 12 to 18 months of
Stanoszek et albeginning imatinib treatmentwere100%free fromaccelerated-
phase or blast crisis at 5 years.18 A subsequent 0.5-log10
increase in BCR-ABL1 transcript abundance from treated
baseline indicates treatment resistance and the need to begin
a second-generation tyrosine kinase inhibitor or plan for allo-
geneic stemcell transplantation.19e21NationalComprehensive
Cancer Network Guidelines recommend BCR-ABL1 moni-
toring every 3 months to provide fusion transcript-level trend
data.19,20,22 Timely BCR-ABL1 monitoring is essential to
identify patients who are unresponsive to therapy in the early
phase of treatment. Therefore, an accurate baseline or
normalized value of BCR-ABL1 fusion transcript abundance
must be obtained at the time of diagnosis and subsequent BCR-
ABL1 levels must be accurately measured to monitor thera-
peutic efﬁcacy over time.18
Several quantitativeRT-PCRebasedBCR-ABL1diagnostic
tests are commercially available. In addition, standardized
methods have been developed for clinical laboratory measure-
ment of BCR-ABL1 in whole blood,4,22,23 including use of the
International Scale for interlaboratory harmonization.24e29 The
International Randomized Interferon versus STI-571 study
standardized diagnostic baseline is deﬁned as 100% Interna-
tional Scale value, and MMR is deﬁned as 0.1% International
Scale value.30 BCR-ABL1 measurement results are converted
to the International Scale via use of the World Health Organi-
zation panel of reference reagents with designated BCR-ABL1
International Scale values.31,32
An element missing from existing BCR-ABL1 tests is
adequate control for intersample variation in PCR-interfering
substances and interreaction variation in quality and quantity
of PCR reagents or thermal cycling efﬁciency. These prob-
lems could cause inaccurate and possibly false-negative
results. To address this, in the method described herein,
BCR-ABL1 and b-glucuronidase (GUSB) were each
measured relative to a known number of respective synthetic
internal standard (IS) molecules.
Another potential source of inconsistency in BCR-ABL1
measurement is variation in the efﬁciency of mRNA-to-
cDNA conversion during reverse transcription (RT). Blood-
speciﬁc inhibitors of RT may be present within RNA
extracted from whole blood, including heme, IgG, leukocyte
genomic DNA, and the anticoagulants, EDTA and hep-
arin.33e37 RNA extracted from whole blood is mostly from
leukocytes; however, a fraction of the RNA came from
reticulocytes. Reticulocytes contribute an abundance of
interfering a- and b-globin mRNA that may compete with
lowly expressed transcripts, such as BCR-ABL1 for reagents
within an RT reaction.38,39 Reverse transcription efﬁciency is
also dependent on the priming method used.
Clinical laboratories that conduct BCR-ABL1 molecular
monitoring generally analyze whole blood samples collected
in tubes containing EDTA to prevent coagulation-associated
cytolysis. However, even in such tubes, relative representa-
tion of certain genes may change as early as minutes after
venipuncture because of an altered regulation and/or degra-
dation rate.40,41 Thus, there is a need to identify the optimal392RT priming method for both BCR-ABL1 and the reference
gene, GUSB, under the most optimal storage time. The
optimal amount of whole blood RNA to include in the RT
reaction may be affected by each of the previously mentioned
factors.
In an effort to establish optimal conditions for measure-
ment of BCR-ABL1, we did the following: i) developed
a quality-controlled, quantitative PCR method, ii) measured
the effect of total RNA input or type of RT primers on RT
efﬁciency, and iii) assessed the effect of storage time on
BCR-ABL1 measurement.
Materials and Methods
Samples from CAP MRD-BeBCR-ABL1 p210 2011
Proﬁciency Survey
Three proﬁciency samples were obtained from the College
of American Pathologists (CAP; Northﬁeld, IL). Sample
minimal residual disease (MRD)-04 was RNA extracted
from the K562 cell line that expresses the b3a2 BCR-ABL1
transcript. Sample MRD-05 was RNA extracted from
a BCR-ABL1enegative cell line. Sample MRD-06 was
RNA extracted from MRD-04 diluted 1:10,000 in BCR-
ABL1enegative RNA (MRD-05).42 Each RNA sample was
DNase treated with DNA-free DNAse Treatment and
Removal Reagent (Life Technologies, Grand Island, NY).
Blood Samples
All blood samples were collected under protocols approved
by the University of Toledo (Toledo, OH) Medical Center
Institutional Review Board. Whole blood samples were
collected in 4-mL dipotassium EDTA Vacutainer tubes
(Becton Dickinson, Franklin Lakes, NJ) at ambient
temperature at the University of Toledo Medical Center.
Blood used to mix with K562 cells (described later) was
obtained through the Department of Pathology, University
of Toledo Medical Center, from patients undergoing routine
venipuncture for laboratory testing. Leftover blood not
needed for standard-of-care purposes from patients with
a normal complete blood cell count was anonymized and
provided to the research laboratory. Peripheral blood was
obtained from three patients with CML [two with chronic-
phase (CP) CML newly diagnosed and one with CP-CML at
MMR under treatment] at the same time blood was drawn
for shipment to ARUP Laboratories (Salt Lake City, UT) for
BCR-ABL1 measurement and conversion of results to the
International Scale.
Samples for Kinetic Stability Study
The K562 cell line, expressing the BCR-ABL1 b3a2 fusion
transcript, was purchased from ATCC (Manassas, VA) and
incubated in RPMI 1640 medium þ 10% fetal bovine serum
at 37C, in an atmosphere containing 5% CO2 and 90%jmd.amjpathol.org - The Journal of Molecular Diagnostics
Quality Control in BCR-ABL1 Analysishumidity. K562 cells were isolated from culture at 80%
conﬂuency. In each of the two experiments, whole blood
samples were collected in EDTA tubes from three anony-
mized individuals, and each sample was spiked with a known
number of K562 cells suspended in PBS. In the ﬁrst exper-
iment (samples A, B, and C), the concentration of K562 cells
in each whole blood sample was 5.8  105 cells/mL (2.32 
106 cells total), and in the second experiment (samples D, E,
and F), the concentration in each sample was 4.7 106 K562
cells/mL (1.88  107 cells total). Each whole blood/K562
cell sample was incubated in 15-mL conical tubes at room
temperature for various amounts of time. For each sample,
the time course was initiated within 6 hours of venipuncture.
At each time point, individual conical tubes were inverted
three times before RNA extraction.
Sample for Comparison of Three RT Priming Methods
Study
Known numbers of K562 cells were spiked into anony-
mized whole blood samples collected in EDTA tubes from
one anonymized individual (K). The concentration of K562
cells in sample K was 5.8  105 cells/mL (2.32  106 cells
total).
Samples for RNA Input versus RT Priming Method Study
Known numbers of K562 cells were spiked into anony-
mized whole blood samples collected in EDTA tubes from
each of three individuals (G, H, and I) for the random
hexamer (RH)eprimed RT efﬁciency study. The concen-
tration of K562 cells was 4.4  106 K562 cells/mL (1.76 
107 cells total) in samples G and H and 5.0  106 K562
cells/mL (2.00  107 cells total) in sample I. For the gene-
speciﬁc primed RT efﬁciency study, blood from one ano-
nymized individual (J) was used. The concentration of K562
cells was 4.9  106 K562 cells/mL (1.76  107 cells total).
Preparation of RTSM
In vitroetranscribed synthetic, alien RNA standards devel-
oped by the External RNA Control Consortium (ERCC),
termed ERCC 171 and 113, were donated by Dr. Marc Salit,
National Institute for Standards and Technology (Gaithers-
burg, MD).43e45 RNA stocks from ERCC 113 and 171
standards were ﬁrst diluted in RNase-free water, and the
RNA concentration was measured using a Nanodrop 2000
spectrophotometer (Thermo Scientiﬁc, Wilmington, DE).
ERCC 113 and 171 standards were each secondarily diluted
in 100 ng/mL salmon sperm DNA to a ﬁnal concentration of
1.0 (1010) mol/L (Invitrogen, Carlsbad, CA). The ERCC
113 standard was reverse transcribed into cDNA, and the
cDNA was quantiﬁed using the Agilent 2100 Bioanalyzer
(Agilent, Palo Alto, CA). A reverse transcription standards
mixture (RTSM) was prepared by combining known molar
amounts of ERCC 171 RNA and ERCC 113 cDNAThe Journal of Molecular Diagnostics - jmd.amjpathol.org(previously reverse transcribed). A 1-mL aliquot of RTSM
was included in each RT reaction to assess RT efﬁciency.
The ERCC 171 RNA was reverse transcribed into cDNA,
along with other RNA species in the RT reaction, whereas
the ERCC 113 cDNA remained unchanged. Yield of ERCC
171 cDNA was a measure of RT efﬁciency, and ERCC 113
cDNA was included as a sample loading control. Each 1-mL
aliquot of RTSM contained 1.42  104 (6.7  103) ERCC
171 cDNA molecules and 1.68  104 (7.4  103) ERCC
113 cDNA molecules when measured in RT reactions with
no background RNA.
Measurement of RT Efﬁciency
After RT, an aliquot of RT product, cDNA, was subjected to
PCR in the presence of a known number of IS molecules for
ERCC 171 and ERCC 113. ERCC 171 RNA RT efﬁciency
was determined by measuring the ERCC 171 cDNA native
template (NT)/IS PCR product ratio over the ERCC 113
NT/IS product ratio. In this way, normalization of ERCC
171 cDNA molecules to ERCC 113 cDNA molecules
controlled for variation in RTSM sample loading, enabling
reliable measurement of RT efﬁciency.
Sequencing of Background Peaks
PCR products associated with the background noise peaks
were isolated using anE-Gel SizeSelect 2%gelwith the E-Gel
iBase Power System (Invitrogen), and tailed BCR-ABL1
b3a2 sequencing primers corresponding to Ion Torrent
Amplicon Sequencing adapters were used to amplify both
isolated native and off-target products (Ion Torrent Amplicon
Application Note, April 4, 2011; Amplicon Sequencing,
South San Francisco, CA). Ampliﬁed products with attached
Ion Torrent Amplicon Sequencing adapters were gel puriﬁed
using E-Gel Size Select 2% and sent to the Ohio University
Genomics Facility for Ion Torrent 314DNAChip Sequencing
Service (Ohio University, Athens, OH). Sequencing data
captured internally to the sequencing reagents were used
to build consensus sequences using ClustalX 2.1 (Conway
Institute UCD, Dublin, Ireland).46 These consensus se-
quences were then subjected to BLAST search of the National
Center for Biotechnology Information human genomic and
transcript databases (http://blast.ncbi.nlm.nih.gov/Blast.cgi,
last accessed December 18, 2012).
RNA Extraction
RNA was extracted with the QIAamp RNA Blood Mini Kit
provided by QIAGEN (Hilden, Germany), according to the
manufacturer’s protocol. Each QiaAmp spin-column can
prepare up to 1.5 mL of human whole blood. Each RNA
sample was eluted with RNase-free water. In the kinetic
cytolysis and RT primer comparison studies, RNA was
extracted from single 1-mL anonymized whole blood/K562
samples per individual. In the RNA input versus RT393
Stanoszek et alefﬁciency study, RNA was extracted from four separate spin
columns (1 mL each) with the same eluate volume of
RNase-free water applied to each of the four columns.
For the low BCR-ABL1 RNA RT priming comparison,
patient blood sample RNA with undetectable BCR-ABL1
levels was extracted using the QiaAmp RNA Blood Mini
Kit (QIAGEN). Extracted patient blood RNA was mixed
with a 0.6-mL K562 cell RNA (5.66 ng/mL) that was
extracted using TriREAGENT (Molecular Research Center,
Inc., Cincinnati, OH).
For all samples, RNA concentration and purity were each
measured using aNanodrop 2000 spectrophotometer (Thermo
Scientiﬁc, Wilmington, DE). RNA integrity was evaluated on
an Agilent 2100 Bioanalyzer for quantiﬁcation and charac-
terization of 28s and 18s ribosomal RNA bands. Agilent
software version B.02.03.SI307 calculated an RNA integrity
number (RIN) for each sample assessed. RNA samples were
stored at 20C.
Reverse Transcription
All total RNA samples were reverse transcribed using the
Superscript III First Strand Synthesis System for RT-PCR
(Invitrogen). A 30-mL RT reaction volume was used and
contained 0.5 mg total RNA (kinetic stability study), various
RNA inputs, including 0.9, 3, 5, 9, and 18 mg (RT input
study), or 1.0 mg total RNA (RT priming comparison study).
Reverse transcription reaction volumes were increased for
experiments, including the CAP Proﬁciency Sample Study
(75 mL) and the CML Patient Study (subject 806, 40 mL; and
subjects 807 and 808, 60 mL). In a 30-mL RT reaction, sample
RNA in 12 mL RNase-free water was denatured by 5-minute
incubation at 94C and then placed on ice to cool. An 18-mL
RT master mix was then added, and the RT reaction mixture
was incubated at 50C for 1 hour, followed by 5-minute
incubation at 94C. The RT master mix included the
following: 10 RT buffer, 25 mmol/L MgCl2, 0.1 mol/L
dithiothreitol, 10 mmol/L dNTP mix, 40 U/mL RNaseOUT,Table 1 Primer and IS Sequences
Target
Primers
Forward R
BCR-ABL1 b3a2 (b2a2) 50-ACTCCAGACTGTCCACAGCA-30 5
GUSB 50-GACTGAACAGTCACCGACGA-30 5
ERCC 113 50-TTGGATCAGTGGGAAGTGCT-30 5
ERCC 171 50-AAGCTGACGGTGACAAGGTT-30 5
Internal Standard
BCR-ABL1 b3a2
(and b2a2)
50-ACTCCAGACTGTCCACAGCATTCCGCT
ACTTTGAGCCTCAGGGTCTGAGTGAAG
GUSB 50-GACTGAACAGTCACCGACGAGAGTGCTG
GCAGCGTTCCTTTTGCGAGAGAGATACT
ERCC 113 50-TTGGATCAGTGGGAAGTGCTCACGCGC
GTTCGTCACGCCCTAGTACCTTTCGAG
ERCC 171 50-AAGCTGACGGTGACAAGGTTTCCCCCT
AGAGTTGGATTTGAGGAAAACTGCGAA
394and 200 U/mL SuperScript III RT with 25 mmol/L RH,
50 mmol/L oligo (d)T primers, or 3 mmol/L gene-speciﬁc
primers (Invitrogen). The PCR reverse primer was used as
the gene-speciﬁc RT primer for GUSB, whereas BCR-ABL1
gene-speciﬁc RT primers included either the PCR reverse
primer (19 bases) or an extended primer (29 bases).
Transcript Abundance Measurement
Sample loading was controlled by measuring BCR-ABL1
relative to GUSB.47e49 According to the standardized RT-
PCR method, BCR-ABL1 and loading control gene,
GUSB, were each measured relative to a known number of
their respective IS molecules within an Internal Standards
Mixture (ISM).50,51 The ISM used for these studies was
purchased from Accugenomics, Inc. (Wilmington, NC).
Transcript abundance values were then calculated as BCR-
ABL1 molecules per 103 GUSB molecules. The competi-
tive template IS for BCR-ABL1 and GUSBwere each 10% to
20% shorter than the target gene NT PCR product, but both
were ampliﬁed with the same efﬁciency by the same pair of
primers. BCR-ABL1 b3a2 and b2a2 fusion transcript cDNAs
were measured with the same BCR-ABL gene-speciﬁc PCR
forward and reverse primer and measured relative to the same
IS sequence. BCR-ABL1 b3a2 and b2a2 PCR products were
different lengths that could be electrophoretically separated.
Sequence information for primers and IS is provided in
Table 1. The presence of an IS controlled for sample loading,
intersample variation in the presence of PCR inhibitors
(which often are gene speciﬁc), and ensured no false nega-
tives (if the PCR failed, the IS PCR product was not observed
and there were no data to report).51 False positives due to
contamination were eliminated through use of a control PCR
sample with neither native nor competitive template.
Before ampliﬁcation, cDNA and ISM were combined
into a master mix, along with the appropriate volume of
RNase-free H2O, 30 mmol/L 10 buffer containing MgCl2
(Idaho Technology, Salt Lake City, UT), 2 mmol/L dNTPseverse NT length IS length
0-TTGGGGTCATTTTCACTGG-30 231 (164) 123
0-GTAAACGGGCTGTTTTCCAA-30 174 139
0-GGGGCTCGAAAGGTACTAGG-30 130 102
0-TCGCAGTTTTCCTCAAATCC-30 118 97
GACCATCAATAAGGAAGAAGCCCTTCAGCGGCCAGTAGCATCTG
CCGCTCCCAGTGAAAATGACCCCAA-30
GGGAATAAAAAGGGGATCTTCACTCGGCAGAGACAACCAAAAAGT
GGAAGATTGCCAATGAAATTGGAAAACAGCCCGTTTAC-30
GGAGCCCACTGGGCGAACAGCAACGTTATAACGGCCACTCAGTG
CCCC-30
AATCGAGACGCTGCAATAACACAGGGGCATACAGTAACCAGGCA
AAA-30
jmd.amjpathol.org - The Journal of Molecular Diagnostics
Figure 1 Interlaboratory comparison ofBCR-ABL1measurement.A: Log10
reduction of BCR-ABL1 per 103 GUSB measurement in CAP MRD-Be
BCR/ABL1 p210 2011 Survey measured at the University of Toledo Medical
Center (UTMC) compared with median log10 reduction values of survey
participants. B: Comparison of BCR-ABL1 per 103 GUSB measurement to
International Scale percentage values reported by ARUP Laboratories in three
CML patient blood samples (two with CP-CML newly diagnosed without
treatment and one with CP-CML at MMR under treatment). Gene-speciﬁc RT
primerswere used for newly diagnosed CMLpatient samples, andRHRTprimers
were used for the MMR CML patient sample. The UTMC data presented are
means for three or more replicate measurements. Error bars, SD of the means.
Quality Control in BCR-ABL1 Analysis(Promega, Madison, WI), 50 ng/mL gene-speciﬁc primers,
and a minimum of 0.5 U Taq polymerase (Promega). For
PCR ampliﬁcation of blood/K562 cDNA samples that had
been reverse transcribed with the 29-base BCR-ABL1 RT
gene-speciﬁc primer, a minimum of 0.5 U of Gotaq Hotstart
polymerase (Promega) was used. For each experiment,
sufﬁcient master mixture was prepared to measure each of
the desired genes. This mixture was divided into tubes
containing primers for single genes. All PCRs were per-
formed in a Rapidcycler (Idaho Technology) for 35 cycles.
All reactions were denatured for 5 seconds at 94C (2
minutes at 94C for Gotaq Hotstart polymerase in the ﬁrst
cycle), annealed for 10 seconds at 58C, and elongated for
15 seconds at 72C. After PCR ampliﬁcation, the IS and NT
for each gene were electrophoretically separated and quan-
tiﬁed on an Agilent 2100 Bioanalyzer using DNA chips
with DNA 1000 kit reagents for visualization, according
to the manufacturer’s protocol (Agilent Technologies
Deutschland GmbH, Waldbronn, Germany). Area under the
curve values for the NT and IS electrophoretic peaks for
each gene were used for gene expression measurement.
Statistical Analysis
Eachmeasurement was performed in at least triplicate. Results
were expressed as means  SD. Statistical signiﬁcance was
calculated using a Student’s t-test fromData Analysis Tools in
Microsoft Ofﬁce Excel (Microsoft Corporation, Redmond,
WA), and ﬁgures were generated with GraphPad Prism
version 6 (GraphPad Software Inc., La Jolla, CA). The
differences were considered signiﬁcant if P < 0.05.
Results
CAP MRD-BeBCR-ABL1 p210 2011 Proﬁciency Survey
Sample Study
BCR-ABL1 b3a2 per 103 GUSB values were measured in
the three CAP proﬁciency samples. As expected, BCR-
ABL1 b3a2 was not detected in BCR-ABL1enegative
sample MRD-05. Compared with baseline sample MRD-04,
BCR-ABL1 per 103 GUSB was 3.55-log10 lower in sample
MRD-06 (Figure 1A). As indicated in the ﬁgure, this result
was not signiﬁcantly different from the mean difference
measured by other laboratories in the survey.
Patient Sample Comparison between BCR-ABL1 per 103
GUSB and International Scale Values
Changes in BCR-ABL1 per 103 GUSB values were closely
correlated with changes in values measured by ARUP
Laboratories for the three CML patient samples. ARUP
Laboratories measured BCR-ABL1 relative to ABL1 and
converted values to the International Scale. A linear trend-
line ﬁt BCR-ABL1 per 103 GUSB to International Scale
data points with high correlation (R2 Z 0.99) (Figure 1B).The Journal of Molecular Diagnostics - jmd.amjpathol.orgEffect of Incubation at Room Temperature on
BCR-ABL1 per 103 GUSB Values
BCR-ABL1 per 103 GUSB transcript abundance and RIN
score were measured at each time point and plotted as change
relative to baseline (undegraded) values (Figure 2). When
data from six anonymized individuals were combined, the
BCR-ABL1 per 103 GUSB mean value trended down at 24
hours but was not signiﬁcantly decreased until 48 hours (51%
decrease, P Z 0.004). Relative to baseline, the RIN score
remained unchanged across all time points measured.
RT Primer Effect on Yield of BCR-ABL1 b3a2 or GUSB
We compared oligo (d)T, RH, and gene-speciﬁc RT primers to
determine which gave the greatest yield of BCR-ABL1 and
GUSB cDNA (Figure 3A). For both BCR-ABL1 b3a2 and
GUSB,withRNA input into theRT reactionheld constant (1mg
RNA/RT), the highest yield of cDNAwas obtainedwith the use
of gene-speciﬁc primers in the RT reaction. The yield with
gene-speciﬁc primers was 17-fold (P Z 0.0001) and 21-fold
(P Z 0.0008) higher for BCR-ABL1 b3a2 and GUSB,
respectively, compared with RH (Figure 3A). Because
the yield of each gene increased about the same amount,395
Figure 2 Effect of storage time on BCR-ABL1 measurement and RIN
score. Effect of incubation at room temperature on BCR-ABL1 per 103 GUSB
measurement and RIN score value relative to baseline time equal to 0 hours.
RNA was extracted from whole blood collected in EDTA tubes, mixed with
K562 cells, and then incubated at room temperature for 3 days. The random
hexamers were used for reverse transcription. Asterisks denote statistical
signiﬁcance (P < 0.01) from baseline measurement at 0 hours. The results
are means for samples from six donors, with three or more replicate
measurements of each sample.
Figure 3 Effect of RT primer and RNA input on measured transcript
abundance. A: Effect of RT priming method on yield of BCR-ABL1 b3a2 and
GUSB molecules/PCR assay and BCR-ABL1 b3a2 per 103 GUSB measurement
after quantitative RT-PCR of RNA extracted from whole blood/K562 mixture
with high level of BCR-ABL1 transcript. GSP-19, gene-speciﬁc (19-base)
primer. B: Effect of blood/K562 cell mixture RNA concentration in a 30-mL
RT reaction and RT priming method on yield of BCR-ABL1 b3a2 or GUSB
cDNA relative to RH-primed baseline (0.9 mg RNA/RT). Asterisk denotes
baseline measurements on graph from which fold-changes were deter-
mined. GSP-RT is gene-speciﬁc primed RT reaction, and RH-RT is RH-primed
RT reaction. C: Effect of RNA input on RH-primed RT efﬁciency. RT efﬁciency
is ERCC 171/113 measurement normalized to ERCC 171/113 measurement
for 0 mg RNA input. The results are means for samples with three or more
replicate measurements of each sample. Error bars, SD of the means.
Stanoszek et alnormalized (BCR-ABL1 b3a2 per 103 GUSB) values,
measured with RH versus gene-speciﬁc RT primers, were not
signiﬁcantly different. In contrast, the BCR-ABL1 yield with
oligo (d)T primers was fourfold lower (P Z 0.0007) and
GUSB cDNA yield was 17-fold higher (P Z 0.0001) with
oligo (d)T compared with RH primers (Figure 3A). Because
the effect was different on BCR-ABL1 and GUSB, BCR-
ABL1 b3a2 per 103 GUSB values were signiﬁcantly dif-
ferent compared with those from RH or gene-speciﬁc primers
(PZ 0.0001).
Effect of RNA Input and RT Primer on Yield of
BCR-ABL1 b3a2 or GUSB cDNA
When RH primers were used in RT, a maximum threefold
increase (P Z 0.003) in BCR-ABL1 b3a2 (molecules/mL
cDNA) was observed at 18 mg RNA/RT compared with
baseline at 0.9 mg RNA/RT. Because the slope for GUSB
was not signiﬁcantly different from that for BCR-ABL1
(P  0.35), there was no signiﬁcant difference among the
BCR-ABL1 b3a2 per 103 GUSB values for each level of
RNA input (Figure 3B).
The effect of increasing RNA input into RT reactions using
gene-speciﬁc RT priming was also tested. Yields of BCR-
ABL1 and GUSB molecules/mL cDNA were 17- and 20-fold
higher, respectively, at baseline 0.9 mg RNA/RT reaction
(30 ng RNA/mL cDNA) compared with samples primed with
RH (Figure 3B). Consequently, with gene-speciﬁc primers,
at 18 mg RNA/RT reaction (600 ng RNA/mL cDNA),
BCR-ABL1 and GUSB yields were 158- and 312-fold
higher, respectively, with gene-speciﬁc RT priming
compared with RH RT priming. As with the cDNA from
RH RT, because the slope for GUSB was not signiﬁcantly
different from that for BCR-ABL1 (P  0.35), there was no396signiﬁcant difference among the BCR-ABL1 b3a2 per 103
GUSB values for each level of RNA input.
RNA Input Effect on RT Efﬁciency with RH
(ERCC 171/113)
The RTSM (as described in Materials and Methods) was
used to directly measure whether reduced cDNA yield withjmd.amjpathol.org - The Journal of Molecular Diagnostics
Figure 4 Effect of extended BCR-ABL1 gene-speciﬁc RT primer on
target speciﬁcity. A: Agilent Bioanalyzer electropherograms demonstrating
(top line) off-target reverse transcription priming with 19-base BCR-ABL1
gene-speciﬁc RT primer with sample having low level BCR-ABL1. NT and IS
product peaks are outcompeted in PCR by RANBP3 transcript isoforms
(bottom line), presence of clean NT and IS peaks with 29-base BCR-ABL1
gene-speciﬁc RT primer. B: Effect of RT priming method on BCR-ABL1 b3a2
per 103 GUSB measurement after reverse transcription of low level of BCR-
ABL1 transcript in a blood background. GSP-29, gene-speciﬁc primer
(29 bases). The data presented are means for three or more replicate
measurements. Error bars, SD of the means.
Quality Control in BCR-ABL1 AnalysisRH was the result of RT inhibition. Compared with baseline
(0 mg background RNA/RT), ERCC 171/113 RT efﬁciency
with RH primers was reduced by 52% (P Z 0.02) at 3 mg
RNA/RT (100 ng RNA/mL cDNA) and reduced by 80%
(P Z 0.002) at 18 mg RNA/RT (600 ng RNA/mL cDNA).
A semilog plot trend line ﬁts the data points with high
correlation (R2Z 0.98) (Figure 3C). ERCC 171/113 valuesTable 2 Homology of BCR-ABL1 Gene-Speciﬁc RT Priming Site in ABL
Transcript or primer
ABL1 transcript
BCR-ABL1 19-nucleotide gene-speciﬁc RT primer
RANBP3 transcript isoform family
BCR-ABL1 29-nucleotide gene-speciﬁc RT primer
Thew symbol represents a small insertion sequence (two to ﬁve bases) seen in
boldfaced.
The Journal of Molecular Diagnostics - jmd.amjpathol.orgwere measured in the same RH-primed cDNAs used in
Figure 3B.
Extended BCR-ABL1 Gene-Speciﬁc RT Primer Effect on
Yield of BCR-ABL1 per 103 GUSB Values
Although use of gene-speciﬁc primers in RT markedly
increased cDNA yield and, therefore, has the potential to
signiﬁcantly increase the sensitivity of the BCR-ABL1 test,
the 19-base, gene-speciﬁc BCR-ABL1 RT primer caused
high background noise in the electropherogram when a low
level of BCR-ABL1 was loaded (Figure 4A). In an effort to
identify and eliminate the source of this high background,
PCR products associated with the background noise peaks
were isolated and sequenced. Greater than 95% of the
generated consensus sequences mapped to the RANBP3
gene (Entrez Gene ID 8498) and its multiple splice iso-
forms, RANBP3-a, RANBP3-b, and RANBP-d. Based on
this mapping, we identiﬁed signiﬁcant homology between
the 19-base, gene-speciﬁc BCR-ABL1 RT primer used and
the RANBP3 transcript isoform family (Table 2). We
hypothesized that these splice variants resulted in non-
speciﬁc electrophoretic peaks at lower input concentra-
tions of BCR-ABL1 native product. To test this hypothesis,
we lengthened the 19-base, gene-speciﬁc BCR-ABL1 RT
primer by 10 bases at the 30 end to minimize homology of
the gene-speciﬁc BCR-ABL1 RT primer to the RANBP3
transcript isoform family.
In contrast to the 19-base RT primer, when low-level
BCR-ABL1 was loaded into the RT reaction with 29-bp RT
primer, the electrophoretic background noise was low
(Figure 4A). Compared with yields obtained with RH, use
of the extended BCR-ABL1 gene-speciﬁc RT primer and
the original GUSB gene-speciﬁc RT primer increased BCR-
ABL1 b3a2 yield by 8.5-fold (P Z 0.03) and GUSB yield
by 6.6-fold (PZ 0.007), respectively, in RNA samples with
low BCR-ABL1 levels. Because the yield of each gene was
increased about the same amount, normalized (BCR-ABL1
b3a2 per 103 GUSB) values measured with RH versus gene-
speciﬁc RT primers were not signiﬁcantly different (P Z
0.17) (Figure 4B).
Discussion
Accurate measurement of BCR-ABL1 load in peripheral
blood samples is necessary for optimal management of1 Transcript and RANBP3 Transcript Isoform Family
Sequence
50-CCTTCTCGCTGGACCCAGTGAAAATGACCCCAA-30
50-TTGGGGTCATTTCACTGG-30
50-GAGGAGAAAGAGCCCCAGwAAAAATGAGTCCAG-30
50-TTGGGGTCATTTTCACTGGGTCCAGCGAGAAGGT-30
a small fraction of captured splice variants (<1%). Complementary bases are
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Stanoszek et alchronic myelogenous leukemia. The test and methods that
we have developed should enable reliable interlaboratory
comparison of results. The values obtained with the BCR-
ABL1 kits have high correlation with results obtained in the
CAP MRD-BeBCR-ABL1 p210 2011 Survey and from
analysis of CML patient samples with an established
commercial test in a clinical laboratory. The synthetic
internal standards used in this kit were prepared in large
volume and are stable, so that they may be shared with other
laboratories. This approach enables reliable interlaboratory
comparison and controls for intersample variation in inter-
fering substances, interexperimental variation in quality or
quantity of PCR reagents, and/or thermal cycler perfor-
mance, all factors that may lead to incorrectly low measured
values or false negatives. In addition, use of gene-speciﬁc
primers in RT increased the sensitivity of the test by at least
10-fold to a maximum of 100-fold compared with RH
primers, depending on the amount of RNA input in the RT
reaction. This will enable reduction in amount of RNA
required and/or measurement of MMR at a log-lower level.
To ensure reliable BCR-ABL1 measurement in clinical
testing, it is clear that, in clinical application, optimal RT
conditions, including primers and RNA input, should be
established and adhered to, and that blood storage time before
measurement should be kept to a minimum and kept rela-
tively constant. The effects of varying these conditions are of
sufﬁcient magnitude to affect reliability of measuring a 0.5-
log10 increase in BCR-ABL1 load, an accepted indication of
treatment failure, and thereby could negatively affect patient
treatment. We conclude that optimal measurement of BCR-
ABL1 per 103 GUSB in whole blood is obtained when
gene-speciﬁc primers are used in RT, and samples are pro-
cessed within 24 hours after blood collection.
For monitoring CML, patient blood samples typically are
collected at one site and then shipped to a specialized labora-
tory at a different site for BCR-ABL1 testing. Consequently,
RNA may not be extracted from blood samples until >48
hours after collection. Our results, such as those of van der
Velden52 andMoravcova53 and colleagues, suggest that blood
samples kept at ambient temperature for extended amounts of
time result in altered BCR-ABL1 measurement. Speciﬁcally,
BCR-ABL1 b3a2 per 103 GUSB values decreased by
approximately 50% in 48 hours (Figure 2). Such a sizable
decrease, combined with other sources of analytical variation,
could mask a 0.5-log10 increase. A delay of change in treat-
ment as the result of inaccurate BCR-ABL1 measurement
could lead to decreased survival time for patients. Although
RIN score is commonly used as a measurement of RNA
integrity, in this study, it was an insensitive indicator of RNA
degradation. However, RIN score may be useful as a conve-
nient ﬁrst analysis.
To be effective, the BCR-ABL1 measurement method
used for molecular CML monitoring must reliably measure
low copy numbers. In quantitative RT-PCRebased assays
that measure BCR-ABL1 load, the sensitivity of BCR-ABL1
detection can be heightened by increasing the amount of398extracted RNA from patient samples into the RT reaction
before PCR ampliﬁcation. Because of increased analyte load,
there is an advantage to loading up to 600 ng RNA/mL
reaction (18 mg RNA/30 mL reaction) when RH are used for
priming in the RT reactions. However, when RH are used,
adding more RNA to the RT reaction only marginally
improves sensitivity of BCR-ABL1 detection as the result of
reduced RT cDNA yield (Figure 3B). Analysis with the
RTSM conﬁrmed that increasing RNA in the RT reaction
inhibits RH-primed RT. Possible causes of decrease in RT
efﬁciency in these conditions include limiting substrates,
increased presence of blood-speciﬁc RT inhibitors, or
a combination of both. In studies not presented, attempts to
optimize substrate concentrations in RT did not improve RT
efﬁciency with RH priming at a higher RNA load. In contrast,
when gene-speciﬁc RT primers were used, BCR-ABL1 yield
was markedly higher and there was no interference with RT
as the level of RNA input into the RT reaction increased.
When RNA input was increased from 0.9 to 18 mg RNA/30
mL RT reaction, there was a threefold increase in BCR-ABL1
yield with RH but a 158-fold increase with gene-speciﬁc
primers, providing a nearly 50-fold higher yield of BCR-
ABL1 product with gene-speciﬁc primers. Thus, if enough
blood-derived RNA from a sample is available, increasing
the RNA input of the RT reaction to as much as 600 ng RNA/
mL reaction will markedly improve the sensitivity of BCR-
ABL1 detection when gene-speciﬁc RT priming is used,
but will provide only small improvement with RH primers.
Although oligo (d)T primers are commonly used for
reverse transcription of eukaryotic mRNAs with a 30 poly-A
tail, they have reduced RT efﬁciency for BCR-ABL1 fusion
transcript (Figure 3A), possibly because of the presence of
a large distance (approximately 1000 nucleotides) between
the poly-A tail and ABL1 exon 2.24 As a result, BCR-ABL1
molecular monitoring laboratories generally use RH as the
RT primingmethod instead of oligo (d)T primers.30 Although
the use of RH primers allows the reverse transcription of most
transcripts from the same RNA sample, gene-speciﬁc RT
priming is reported to provide more efﬁcient RT of speciﬁc
transcripts.54 Previous studies showed that the use of random
pentadecamer primers increased BCR-ABL1 yield by 86%
compared with RH.55 In our study, gene-speciﬁc RT primers
produced the optimal yield of BCR-ABL1 b3a2 and GUSB
cDNA by generally, 1 to 2 logs more than that obtained with
RH, depending on the RNA input into the RT reaction.
In our construction of the extended BCR-ABL1 gene-
speciﬁc RT primer to eliminate off-target RT priming, we
determined that the RANBP3 transcript isoform Family has
a signiﬁcant degree of sequence homology to ABL1 in exon 2.
This particular ﬁnding is important, because it may enable
optimization of other nucleic acidebased CML monitoring
methods to avoid false-positive measurement of RANBP3
transcripts.
We conclude that use of gene-speciﬁc RT primers will be
optimal for molecular monitoring of BCR-ABL1 load and
that this is especially important when BCR-ABL1 copyjmd.amjpathol.org - The Journal of Molecular Diagnostics
Quality Control in BCR-ABL1 Analysisnumber is low (eg, when patients achieve a major or complete
molecular response). It is recognized that use of RH to prime
blood-derived RNA for cDNA synthesis enables the reverse
transcription of all possible BCR-ABL1 fusion transcripts,
and this is optimal for initial CML diagnosis. However,
because gene-speciﬁc primers have much higher RT efﬁ-
ciency, they are more suitable for monitoring purposes when
the speciﬁc fusion transcript splice variant is known.
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